NeoGenomics Inc NEO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if NEO is a good fit for your portfolio.
News
-
NeoGenomics to Report Second Quarter 2024 Financial Results on July 29, 2024
-
Fort Myers’ Mayor to Proclaim June as NeoGenomics’ Commitment to Cancer Month
-
NeoGenomics to Introduce Comprehensive Lung Solution & Feature Hematopathology Services at ASCO, Offering Actionable Insights to Support Treatment Management
-
NeoGenomics Reports First Quarter 2024 Results
Trading Information
- Previous Close Price
- $15.08
- Day Range
- $14.66–15.51
- 52-Week Range
- $11.03–21.22
- Bid/Ask
- $13.00 / $15.84
- Market Cap
- $1.90 Bil
- Volume/Avg
- 833,547 / 757,109
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 3.11
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Advanced Diagnostics. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. Advanced Diagnostics segment supports pharmaceutical firms in their drug development programs by supporting various clinical trials and research. For Clinical Services, Its specialized diagnostic services are performed based on an online test order or a written test requisition form. The company generates majority of its revenue from Clinical Services.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Stock Style Box
- Small Core
- Total Number of Employees
- 2,100
- Website
- https://www.neogenomics.com
Comparables
Valuation
Metric
|
NEO
|
300639
|
301060
|
---|---|---|---|
Price/Earnings (Normalized) | — | 48.61 | 23.68 |
Price/Book Value | 2.08 | 0.60 | 1.73 |
Price/Sales | 3.11 | 2.60 | 1.80 |
Price/Cash Flow | 63.22 | 13.77 | 6.86 |
Price/Earnings
NEO
300639
301060
Financial Strength
Metric
|
NEO
|
300639
|
301060
|
---|---|---|---|
Quick Ratio | 6.85 | 7.56 | 2.50 |
Current Ratio | 7.48 | 8.11 | 3.03 |
Interest Coverage | — | — | −18.88 |
Quick Ratio
NEO
300639
301060
Profitability
Metric
|
NEO
|
300639
|
301060
|
---|---|---|---|
Return on Assets (Normalized) | −0.34% | −0.07% | −5.18% |
Return on Equity (Normalized) | −0.60% | −0.09% | −8.53% |
Return on Invested Capital (Normalized) | −1.06% | −0.55% | −6.57% |
Return on Assets
NEO
300639
301060
Diagnostics & Research Industry Comparables
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|---|
Thermo Fisher Scientific Inc
TMO
| Btbmtmjq | Trrq | $226.9 Bil | |||
Danaher Corp
DHR
| Lrkcssgyz | Bhwxxv | $197.8 Bil | |||
IQVIA Holdings Inc
IQV
| Dgmnnxc | Vpjrm | $43.7 Bil | |||
Agilent Technologies Inc
A
| Zscnmgkn | Qygvf | $39.4 Bil | |||
IDEXX Laboratories Inc
IDXX
| Tjqyzhhm | Lbtrvz | $38.8 Bil | |||
Mettler-Toledo International Inc
MTD
| Nyqsmyrwk | Dfsgpx | $30.1 Bil | |||
Icon PLC
ICLR
| Sjpxhpr | Hcymsvg | $25.9 Bil | |||
Illumina Inc
ILMN
| Sjkzyksv | Pjyscw | $18.7 Bil | |||
Waters Corp
WAT
| Klkmcrszv | Fnmxm | $18.4 Bil | |||
Labcorp Holdings Inc
LH
| Bsytrmvjc | Lmqzhm | $17.7 Bil |